They are based on the antibacterial activity and pharmacokinetic characteristics of this drug. They take account both of the clinical studies to which it gave rise and of its place in the range of antibacterial products currently available.

They are limited to infections caused by organisms known to be sensitive, in particular to certain situations where the bacterial species responsible for infection can be multiple and / or resistant to the antibiotics currently available.
< Br>

On this basis, this medicinal product is of particular interest in the following indications:

Acute otitis media of the young child, otitis, recurrent

· Sinusitis

· Lower respiratory infections of the child from 30 months to 5 years

· Superinfections of chronic bronchopneumonia

· Recurrent or complicated urinary tract infections, excluding prostatitis

· Severe stomatal infections: abscesses, phlegmons, cellulitis, periodontitis.

Official recommendations concerning the appropriate use of antibacterials should be taken into account.
Posology expressed in amoxicillin

CHILDREN over 30 months

In the patient with normal renal function

80 mg / kg / day in three doses, not exceeding the dosage of 3 g per day.
In patients with renal insufficiency greater than 30 months

Creatinine clearance

Dosage Scheme

Greater than 30 ml / min.

No dosage adjustment required

Between 10 and 30 ml / min.

15 mg / kg / take maximum, twice a day.

Less than 10 ml / min.

15 mg / kg / day maximum.

Hemodialysis: 15 mg / kg / day and 15 mg / kg supplement during and after dialysis.
Administration mode

This medicinal product is administered orally.
Administration is done with the syringe, for oral administration graduated in kg body weight

The dosage per dose is given, depending on the weight of the infant, on the syringe plunger for oral administration graduated in kg. The dose therefore reads directly on the graduations of the syringe for oral administration. Thus, the indicated weight corresponds to the dose for a catch. Three outlets per day are needed. For example, Grade No. 20 corresponds to the dose to be administered per dose for a 20 kg child three times a day.
< Code>
Take the medication preferably at the beginning of the meal.
No information in the marketing authorization.

Pharmacotherapeutic group, ANTIBACTERIANS FOR SYSTEMIC USE, ATC code, J01CR02.

This drug is a combination of amoxicillin and clavulanic acid, a potent, beta-lactamase inhibitor. Clavulanic acid rapidly and irreversibly inhibits most beta-lactamases produced by Gram-positive and Gram-negative bacteria.

Critical concentrations separate sensitive strains from strains of intermediate sensitivity and the latter from resistant strains

S $ 4; mg / l; and R> 16; mg / l
MIC, pneumococcus: S £ 0.5, mg / l and R> 2 mg / l

The prevalence of acquired resistance may vary according to geography and time for some species. It is therefore useful to have information on the prevalence of local resistance, especially for the treatment of severe infections. These data can only provide guidance on the probabilities of the susceptibility of a bacterial strain to this antibiotic.

When the variability of the resistance prevalence in France is known for a bacterial species, it is indicated in the table below


Frequency of resistance, acquired in France (> 10%) (extreme values)


Gram-positive aerobes

Corynebacterium diphtheriae

Enterococcus faecalis

Erysipelothrix rhusiopathiae

Listeria monocytogenes

Nocardia asteroids

Staphylococcus méti-S


Streptococcus bovis

Streptococcus pneumoniae

15 - 35%

Gram-negative Aerobes

Actinobacillus actinomycetemcomitans

Bordetella pertussis

Branhamella catarrhalis

Burkholderia pseudo-mallei



Citrobacter koseri


Escherichia coli

10 - 30%

Haemophilus influenzae

Haemophilus para-influenzae


0 - 20%

Neisseria gonorrhoeae

Neisseria meningitidis

Pasteurella multocida

Proteus, mirabilis

10 - 20%

Proteus, vulgaris


0 - 40%


0 - 30%

Vibrio cholerae


Frequency of resistance acquired in France (> 10%) (extreme values)










Propionibacterium acnes








(In vitro sensitivity, intermediate)

Gram-positive aerobic

Enterococcus, faecium

40 - 80%


Gram-positive aerobic

Staphylococcus, meti-R *

Gram-negative aerobic


Citrobacter; freundii



Morganella, morganii

Proteus rettgeri




Yersinia; enterocolitica








* The frequency of resistance to methicillin is approximately 30 to 50% of all staphylococci and is found mainly in hospital.
Not applicable.

This medicinal product should NEVER be used in cases of

· Allergy to antibiotics of the beta-lactam family (penicillins, cephalosporins): take into account the risk of cross-allergicity with the antibiotics in the group, cephalosporins

· Allergy to any component of the drug

· A history of hepatic involvement related to the association of amoxicillin / clavulanic acid

This medication is GENERALLY NOT RECOMMENDED for use in combination with methotrexate (see section Interactions with other medicinal products and other forms of interaction). Code>
Special warnings

The occurrence of any manifestation, allergic necessitates the cessation of treatment and the setting up of a suitable treatment.

Immuno-allergic reactions, of which severe and sometimes fatal hypersensitivity reactions (anaphylaxis) have been observed exceptionally in patients treated with beta-lactam antibiotics. Code>
Their administration therefore requires an examination for discovery.

In the face of a history of a typical allergy to these products, the contraindication is formal.

Allergy to penicillins is crossed with cephalosporin allergy in 5 to 10% of cases. This leads to the proscription of penicillins when the subject is a known allergic to cephalosporins.

Due to the presence of maltodextrin (glucose), this medication should not be taken by patients with glucose and galactose malabsorption syndrome (rare metabolic diseases).

Precautions for use

As with all beta-lactams, regularly check the blood formula when administering high doses of amoxicillin

The administration of high doses of beta-lactams in patients with renal insufficiency or in patients with predisposing factors such as a history of seizures, epilepsy, treatment or meningeal involvement may exceptionally lead to convulsions

For renal insufficiency, for creatinine clearances less than or equal to 30 ml / min, adjust dosage (see section Dosage and Mode of Administration). >

The risk of occurrence of a hepatic adverse effect (cholestasis) is increased, with treatment greater than 10 days and all, especially after 15 days.
In case of prolonged treatment, it is recommended to monitor the liver and kidney functions.

The combination of amoxicillin / clavulanic acid should be used with caution, in case of hepatic impairment

This medicinal product contains 0.70 mg potassium per dose-graduation or 2.62 mg potassium per ml oral suspension: take this into account in people on a hypokalaemic diet
< Br>

Examinations, paraclinics

Impact on biological parameters

A positivity of the direct Coombs test was obtained during treatment with beta-lactams. This may also occur in subjects treated with amoxicillin / clavulanic acid. False positivations of this test linked to the presence of clavulanic acid have also been observed.

A very high concentrations, amoxicillin tends to

· Decrease the results of blood glucose measurements

· Interferes in the determinations of the total serum protein by color reaction

· Give a false positive color reaction in the glycosuria assays by the colorimetric semi-quantitative method

Associations, deprecated

+ Methotrexate

Increased hematological effects and toxicity of methotrexate by inhibition of renal tubular secretion by penicillins

Associations to be taken into account

+ Allopurinol (and by extrapolation, other inhibitors of uricosynthesis)

Increased risk of skin reactions

Special Problems of the INR imbalance

Many cases of increased oral anticoagulant activity have been reported in patients receiving antibiotics. The marked infectious or inflammatory context, age and general condition of the patient appear as risk factors. In these circumstances, it is difficult to distinguish between infectious pathology and its treatment in the onset of INR imbalance, although some classes of antibiotics are more involved: these include fluoroquinolones , Macrolides, cyclins, cotrimoxazole and certain cephalosporins.

Not applicable.

The manifestations of overdose may be neuropsychic, renal (crystalluria) and digestive. Treatment is symptomatic by monitoring, particularly balance, hydroelectrolyte. Amoxicillin and clavulanic acid can be eliminated by hemodialysis


For amoxicillin there are no reliable data for teratogenesis in animals

In clinical studies, epidemiological studies have not revealed any malformative or fetotoxic effects related to the use of amoxicillin

For clavulanic acid, studies in animals have not demonstrated teratogenicity. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected. Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals during studies, well conducted on two species
< Br>

Clinically, the use of clavulanic acid in a limited number of pregnancies has apparently shown no particular malformative or fetotoxic effects to date. However, further studies are needed to evaluate the consequences of exposure during pregnancy.

Accordingly, the combination of amoxicillin / clavulanic acid may be prescribed during pregnancy if necessary.

The passage of amoxicillin-clavulanic acid into breast milk is low and the amounts ingested are much lower than the therapeutic doses. Accordingly, breast-feeding is possible if this antibiotic is taken.

However, discontinue breast-feeding (or medication) in the event of diarrhea, candidiasis, or rash in the infant.

Candida, diarrhea, loose stools, dyspepsia and abdominal pain.

Digestive symptoms include nausea, vomiting,
Some cases of pseudomembranous colitis and haemorrhagic colitis have been reported.

Allergic manifestations include urticaria, eosinophilia, angioedema, discomfort, respiratory disease, serum sickness, vasculitis, exceptionally anaphylactic shock.
· Maculopapular rash of allergic origin or not

Very rarely, some cases of Lyell and Stevens-Johnson syndrome, erythema multiforme, and exfoliative dermatitis have been reported.

These cutaneous manifestations may be more frequent and / or more intense in patients with infectious mononucleosis or leukemia, the evolving lymphoid.

· Other manifestations have been reported, more rarely

O cases of hepatitis, usually cholestatic, or mixed, have been occasionally reported.These cases appear to occur more readily in elderly and male patients and in treatment of more than 10 days and in particular For treatments, greater than 15 days. Symptoms, such as jaundice which appears to be constant, appear during or at the end of treatment, but may occur a few weeks after discontinuation. The histopathological examination of the liver usually reveals a centro-lobular cholestasis. The evolution is generally favorable but can be extended by a few weeks.
Some extremely rare cases of fatal evolution have been observed.

O moderate and asymptomatic increases in ASAT, ALAT or alkaline phosphatase

O interstitial nephritis, acute

Leucopenia, neutropenia, agranulocytosis, haemolytic anemia, thrombocytopenia, reversible
Cases of seizures have been reported exceptionally (see Warnings and Precautions for Use).

· Very rare cases of superficial dental colorings, usually reversible after brushing, have been reported with the forms, for oral suspension.
Reporting of suspected adverse reactions

The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the ratio, benefit / risk of the drug. Health professionals report any suspected adverse effects via the national reporting system: National Agency for the Safety of Medicines and Health Products (Ansm) and network of Regional Centers, Pharmacovigilance - Website: www.ansm
They are based on the antibacterial activity and pharmacokinetic characteristics of this drug. They take into account both the clinical studies to which it gave rise and its place in the range of antibacterial products currently available, and are limited to infections caused by organisms recognized as sensitive, The bacterial species responsible for the infection may be multiple and / or resistant to the antibiotics currently available, and on this basis it is of particular interest in the following indications: otitis medicaments of the young child, Recurrent infections · sinusitis · low respiratory infections of the child from 30 months to 5 years · superinfections of chronic bronchopneumopathies · recurrent or complicated urinary infections, excluding prostatitis · infections

The official recommendations on the appropriate use of antibacterials should be taken into account.